FR2948573B1 - Nouvelle forme d'administration de complexes de proteines osteogeniques - Google Patents

Nouvelle forme d'administration de complexes de proteines osteogeniques

Info

Publication number
FR2948573B1
FR2948573B1 FR0903803A FR0903803A FR2948573B1 FR 2948573 B1 FR2948573 B1 FR 2948573B1 FR 0903803 A FR0903803 A FR 0903803A FR 0903803 A FR0903803 A FR 0903803A FR 2948573 B1 FR2948573 B1 FR 2948573B1
Authority
FR
France
Prior art keywords
osteogenic protein
administration
protein complexes
new form
coprecipitate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0903803A
Other languages
English (en)
French (fr)
Other versions
FR2948573A1 (fr
Inventor
Gerard Soula
Remi Soula
Olivier Soula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0903803A priority Critical patent/FR2948573B1/fr
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to AU2009317083A priority patent/AU2009317083A1/en
Priority to PCT/FR2009/001332 priority patent/WO2010058106A1/fr
Priority to MX2011005275A priority patent/MX2011005275A/es
Priority to RU2011124917/15A priority patent/RU2011124917A/ru
Priority to JP2011536920A priority patent/JP2012509303A/ja
Priority to SG2011037108A priority patent/SG171388A1/en
Priority to CN2009801546015A priority patent/CN102281868A/zh
Priority to EP09809027A priority patent/EP2376063A1/fr
Priority to US12/591,442 priority patent/US8546356B2/en
Priority to BRPI0916110A priority patent/BRPI0916110A2/pt
Priority to CA2744150A priority patent/CA2744150A1/fr
Priority to KR1020117014109A priority patent/KR20110086752A/ko
Publication of FR2948573A1 publication Critical patent/FR2948573A1/fr
Priority to IL213001A priority patent/IL213001A0/en
Application granted granted Critical
Publication of FR2948573B1 publication Critical patent/FR2948573B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
FR0903803A 2008-11-19 2009-07-31 Nouvelle forme d'administration de complexes de proteines osteogeniques Expired - Fee Related FR2948573B1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FR0903803A FR2948573B1 (fr) 2009-07-31 2009-07-31 Nouvelle forme d'administration de complexes de proteines osteogeniques
BRPI0916110A BRPI0916110A2 (pt) 2008-11-19 2009-11-19 "processo para preparação do co-precipitado, co-precipitado e kit para preparar um implante osteogênico"
MX2011005275A MX2011005275A (es) 2008-11-19 2009-11-19 Nueva forma de administración de complejos de proteína osteogénica.
RU2011124917/15A RU2011124917A (ru) 2008-11-19 2009-11-19 Новая форма введения остеогенных белковых комплексов
JP2011536920A JP2012509303A (ja) 2008-11-19 2009-11-19 骨形成タンパク質複合体の新規投与形態
SG2011037108A SG171388A1 (en) 2008-11-19 2009-11-19 Novel form of administering osteogenic protein complexes
CN2009801546015A CN102281868A (zh) 2008-11-19 2009-11-19 成骨蛋白复合物的新型施用形式
EP09809027A EP2376063A1 (fr) 2008-11-19 2009-11-19 Nouvelle forme d'administration de complexes de protéines ostéogéniques
AU2009317083A AU2009317083A1 (en) 2008-11-19 2009-11-19 Novel form of administering osteogenic protein complexes
PCT/FR2009/001332 WO2010058106A1 (fr) 2008-11-19 2009-11-19 Nouvelle forme d'administration de complexes de protéines ostéogéniques
CA2744150A CA2744150A1 (fr) 2008-11-19 2009-11-19 Nouvelle forme d'administration de complexes de proteines osteogeniques
KR1020117014109A KR20110086752A (ko) 2008-11-19 2009-11-19 골형성 단백질 복합체 투여의 신규한 형태
US12/591,442 US8546356B2 (en) 2008-11-19 2009-11-19 Administration form of osteogenic protein complexes
IL213001A IL213001A0 (en) 2008-11-19 2011-05-19 Novel form of administering osteogenic protein complexes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0903803A FR2948573B1 (fr) 2009-07-31 2009-07-31 Nouvelle forme d'administration de complexes de proteines osteogeniques

Publications (2)

Publication Number Publication Date
FR2948573A1 FR2948573A1 (fr) 2011-02-04
FR2948573B1 true FR2948573B1 (fr) 2011-11-18

Family

ID=41719051

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0903803A Expired - Fee Related FR2948573B1 (fr) 2008-11-19 2009-07-31 Nouvelle forme d'administration de complexes de proteines osteogeniques

Country Status (14)

Country Link
US (1) US8546356B2 (enExample)
EP (1) EP2376063A1 (enExample)
JP (1) JP2012509303A (enExample)
KR (1) KR20110086752A (enExample)
CN (1) CN102281868A (enExample)
AU (1) AU2009317083A1 (enExample)
BR (1) BRPI0916110A2 (enExample)
CA (1) CA2744150A1 (enExample)
FR (1) FR2948573B1 (enExample)
IL (1) IL213001A0 (enExample)
MX (1) MX2011005275A (enExample)
RU (1) RU2011124917A (enExample)
SG (1) SG171388A1 (enExample)
WO (1) WO2010058106A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150079145A1 (en) * 2006-12-14 2015-03-19 DePuy Synthes Products, LLC Protein stabilization formulations
FR2948573B1 (fr) 2009-07-31 2011-11-18 Adocia Nouvelle forme d'administration de complexes de proteines osteogeniques
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2980796B1 (fr) * 2011-09-30 2014-07-04 Adocia Oligosaccharides fonctionnalises
FR2943538B1 (fr) * 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
FR2956116A1 (fr) * 2010-02-09 2011-08-12 Adocia Complexes polysaccharide/bmp-7 solubles a ph physiologique
FR2958647B1 (fr) * 2010-04-08 2013-08-23 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive hydrophobe porte par un spacer au moins trivalent.
WO2011098962A2 (fr) * 2010-02-09 2011-08-18 Adocia Polysaccharides anioniques fonctionnalisés par au moins deux groupements hydrophobes portés par un spacer au moins trivalent
US20140148387A1 (en) * 2010-09-01 2014-05-29 Masahiro Nagaya Freeze-dried recombinant human bone morphogenetic protein-2 preparation
EP2828297A1 (fr) * 2011-05-10 2015-01-28 Adocia Oligosaccharides fonctionnalisés
WO2013021143A1 (fr) * 2011-08-10 2013-02-14 Adocia Solution injectable d'au moins une insuline basale
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
KR102016745B1 (ko) * 2013-02-01 2019-09-02 아이진 주식회사 Ｂｍｐ―７ 및 부형제를 포함하는 흉터 형성의 감소 또는 억제용 조성물
CN103919733A (zh) * 2014-04-11 2014-07-16 聂和民 一种包裹双生长因子的核壳结构微球及其用途
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
JP6663608B2 (ja) * 2014-09-01 2020-03-13 国立大学法人九州大学 骨欠損再建治療用キット、医療用硬組織再建材、製品無機化合物の製造方法及び製品無機化合物
FR3025428A1 (fr) 2014-09-08 2016-03-11 Adocia Composition pharmaceutique stable comprenant du pdgf
EP3040118A1 (en) * 2014-12-29 2016-07-06 Galderma S.A. Ether cross-linked chondroitin hydrogels and their use for soft tissue applications
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
US20190070299A1 (en) 2016-02-23 2019-03-07 Matripharm International Inc. Dual-rate release formulation with high drug loading
CN107596451B (zh) * 2017-08-22 2020-11-20 东南大学 一种基于HA/CS/P(MVE-alt-MA)复合骨修复材料及其制备方法
CN113069591A (zh) * 2021-03-29 2021-07-06 黄河三角洲京博化工研究院有限公司 一种壳聚糖-聚谷氨酸钙生物敷料及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US563461A (en) 1896-07-07 Water elevator and carrier
FR702316A (fr) 1929-10-04 1931-04-04 Bosch Robert Cercle de commande destiné à être fixé sur le volant de direction de voitures
FR805506A (fr) 1936-04-27 1936-11-21 Est Aciers Fins Procédé de fabrication d'aciers fins
FR854621A (fr) 1938-09-29 1940-04-19 Perfectionnements aux procédés de construction et aux briques employées avec ces procédés
US2387201A (en) 1942-01-12 1945-10-16 Bonneville Ltd Mono-acyl ethylene diamines
US4455256A (en) * 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
EP0160103B1 (en) 1983-10-26 1990-06-20 Kanebo, Ltd. Proteinous emulsifier, process for its preparation, and emulsified cosmetic preparation containing same
US5676976A (en) 1995-05-19 1997-10-14 Etex Corporation Synthesis of reactive amorphous calcium phosphates
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
FR2794649B1 (fr) * 1999-06-11 2003-04-11 Solutions Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications
AU2002327007B2 (en) * 2001-09-21 2005-10-20 Stryker Corporation Pore-forming agents for orthopedic cements
TW200518767A (en) * 2003-09-12 2005-06-16 Wyeth Corp Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
FR2861396B1 (fr) 2003-10-24 2005-12-16 Commissariat Energie Atomique Derives amphiphiles de cyclodextrines,leur procede de preparation et leurs utilisations
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
US20070015701A1 (en) 2005-06-01 2007-01-18 Samuel Zalipsky Macromolecular conjugates of bone morphogenetic protein-7
EP1909859B1 (en) * 2005-07-21 2017-09-06 aap Biomaterials GmbH Method for producing hydroxyapatite particles, in particular subnanodisperse hydroxyapatite particles in a matrix
FR2914305B1 (fr) 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
CN100336825C (zh) * 2005-12-20 2007-09-12 山东省医药生物技术研究中心 重组人成骨蛋白－1的制剂制备方法
CN101460523A (zh) * 2006-04-07 2009-06-17 阿道恰公司 双官能化多糖
EP1891984A1 (en) 2006-08-24 2008-02-27 Graftys Macroporous and highly resorbable apatitic calcium-phosphate cement
FR2919188B1 (fr) 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
US20090291114A1 (en) * 2008-04-14 2009-11-26 Adocia Osteogenic composition comprising a growth factor/amphiphilic polymer complex, a soluble cation salt and an organic support
FR2933306B1 (fr) 2008-07-07 2010-09-10 Adocia Composition osteogenique comprenant un complexe facteur de croissance polysaccharide anionique, un sel soluble de cation et une matrice organique
FR2933304A1 (fr) * 2008-07-07 2010-01-08 Adocia Composition synergique osteogenique
FR2934999B1 (fr) 2008-08-13 2011-07-29 Adocia Polysaccharides fonctionnalises par des derives du tryptophane
FR2936800B1 (fr) 2008-10-06 2010-12-31 Adocia Polysaccharide comportant des groupes fonctionnels carboxyles substitues par un derive d'alcool hydrophobe
FR2948573B1 (fr) 2009-07-31 2011-11-18 Adocia Nouvelle forme d'administration de complexes de proteines osteogeniques

Also Published As

Publication number Publication date
MX2011005275A (es) 2011-06-24
SG171388A1 (en) 2011-07-28
AU2009317083A1 (en) 2010-05-27
WO2010058106A1 (fr) 2010-05-27
US20100166867A1 (en) 2010-07-01
US8546356B2 (en) 2013-10-01
KR20110086752A (ko) 2011-07-29
JP2012509303A (ja) 2012-04-19
RU2011124917A (ru) 2012-12-27
IL213001A0 (en) 2011-07-31
FR2948573A1 (fr) 2011-02-04
CA2744150A1 (fr) 2010-05-27
CN102281868A (zh) 2011-12-14
BRPI0916110A2 (pt) 2015-11-03
EP2376063A1 (fr) 2011-10-19

Similar Documents

Publication Publication Date Title
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MX2020002183A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos.
AU2018256635A1 (en) Methods for treating anemia
MY175260A (en) Prion free nanoparticle compositions and methods of making thereof
IL192816A (en) Permanent pattern erasers, pharmaceutical preparations containing them and their use in the preparation of drugs
PH12014501213B1 (en) Aqueous oral care compositions
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
EA201890315A1 (ru) Молекулы антител, связывающие cd22
DK1841332T4 (da) Fortykningsmiddelsammensætning til dysfagipatienter
TW200800967A (en) Benzimidazole thiophene compounds
GEP20156230B (en) Forms of rifaximin and usage thereof
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
NO20090348L (no) Substituerte imidazolonderivater, sammensetninger og anvendelser av samme, samt fremgangsmater for fremstilling av samme
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
MX387756B (es) Composiciones de matríces extracelulares.
PH12013500223A1 (en) Oral care product and methods of use and manufacture thereof
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
PE20142325A1 (es) Composiciones derivadas de la quitosana
EP2528578A4 (en) DENTAL COMPOSITION USING A CALCIUM SOURCE
MY153198A (en) Inhibitors of protein aggregation
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
DE502007005301D1 (de) Verbindungen enthaltend organofluorochlorophosphatanionen
EA200701648A1 (ru) Замещённые пирролы и имидазолы, содержащие их композиции, способ получения и применение
NZ717192A (en) Anti-inflammatory tripeptides
EP2569327A4 (en) EIF4E-BINDING PEPTIDES

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20180330